Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
64.285,01
0,45%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Altimmune Inc (ALT) Altimmune Inc (ALT) Notizie

ALT

Altimmune (ALT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALT
DataOraFonteTitoloSimboloCompagnia
02/05/202413:30GlobeNewswire Inc.Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024NASDAQ:ALTAltimmune Inc
01/05/202413:30GlobeNewswire Inc.Altimmune to Participate at Two Upcoming ConferencesNASDAQ:ALTAltimmune Inc
25/04/202423:24GlobeNewswire Inc.Altimmune Statement on the Passing of Dr. Stephen HarrisonNASDAQ:ALTAltimmune Inc
27/03/202412:00GlobeNewswire Inc.Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALTAltimmune Inc
27/03/202411:57IH Market NewsU.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early TradingNASDAQ:ALTAltimmune Inc
20/03/202412:30GlobeNewswire Inc.Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024NASDAQ:ALTAltimmune Inc
14/02/202418:04Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALTAltimmune Inc
06/02/202400:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALTAltimmune Inc
26/01/202417:49Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALTAltimmune Inc
02/01/202413:30GlobeNewswire Inc.Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024NASDAQ:ALTAltimmune Inc
08/12/202314:35GlobeNewswire Inc.Water Tower Research US Climate Virtual Investor Conference: Presentations Now Available for Online ViewingNASDAQ:ALTAltimmune Inc
04/12/202314:35GlobeNewswire Inc.Water Tower Research US Climate Investor Conference Agenda Announced for December 7th, 2023NASDAQ:ALTAltimmune Inc
30/11/202322:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALTAltimmune Inc
30/11/202322:24GlobeNewswire Inc.Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of PemvidutideNASDAQ:ALTAltimmune Inc
07/11/202322:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALTAltimmune Inc
07/11/202313:00GlobeNewswire Inc.Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:ALTAltimmune Inc
31/10/202312:30GlobeNewswire Inc.Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023NASDAQ:ALTAltimmune Inc
26/10/202314:15Dow Jones NewsAltimmune Gets FDA Fast-Track Designation for Pemvidutide in NASHNASDAQ:ALTAltimmune Inc
26/10/202313:30GlobeNewswire Inc.Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)NASDAQ:ALTAltimmune Inc
25/10/202313:30GlobeNewswire Inc.Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023NASDAQ:ALTAltimmune Inc
17/10/202313:30GlobeNewswire Inc.Altimmune to Participate at Two Upcoming Investor ConferencesNASDAQ:ALTAltimmune Inc
26/09/202313:30GlobeNewswire Inc.Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of DiabetesNASDAQ:ALTAltimmune Inc
12/09/202313:30GlobeNewswire Inc.Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or OverweightNASDAQ:ALTAltimmune Inc
16/08/202322:14Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ALTAltimmune Inc
16/08/202322:10Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ALTAltimmune Inc
10/08/202313:00GlobeNewswire Inc.Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:ALTAltimmune Inc
03/08/202313:30GlobeNewswire Inc.Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023NASDAQ:ALTAltimmune Inc
01/08/202313:30GlobeNewswire Inc.Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)NASDAQ:ALTAltimmune Inc
16/06/202313:30GlobeNewswire Inc.Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023NASDAQ:ALTAltimmune Inc
15/06/202313:30GlobeNewswire Inc.Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023NASDAQ:ALTAltimmune Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALT

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
SRG
Snam
BIT
TEN
Tenaris
BIT
TRN
Terna Trasmissione Elett...
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network